[go: up one dir, main page]

WO1979000115A1 - Procede d'extraction de l'uree des effluents de lavage du sang ou des liquides sanguins - Google Patents

Procede d'extraction de l'uree des effluents de lavage du sang ou des liquides sanguins Download PDF

Info

Publication number
WO1979000115A1
WO1979000115A1 PCT/DE1978/000016 DE7800016W WO7900115A1 WO 1979000115 A1 WO1979000115 A1 WO 1979000115A1 DE 7800016 W DE7800016 W DE 7800016W WO 7900115 A1 WO7900115 A1 WO 7900115A1
Authority
WO
WIPO (PCT)
Prior art keywords
urea
blood
liquids
aldehyde group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1978/000016
Other languages
German (de)
English (en)
Inventor
H Lehmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gambro Dialysatoren GmbH and Co KG
Original Assignee
Gambro Dialysatoren GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gambro Dialysatoren GmbH and Co KG filed Critical Gambro Dialysatoren GmbH and Co KG
Priority to BR7808683A priority Critical patent/BR7808683A/pt
Publication of WO1979000115A1 publication Critical patent/WO1979000115A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1694—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes with recirculating dialysing liquid
    • A61M1/1696—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes with recirculating dialysing liquid with dialysate regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material

Definitions

  • Kidney sufferers are subjected to so-called "blood washing” in order to remove the urea, which is the most important metabolic product of the human protein metabolism in terms of quantity, from the blood.
  • blood washing in order to remove the urea, which is the most important metabolic product of the human protein metabolism in terms of quantity, from the blood.
  • This is done by dialysis or diafiltration with the aid of semi-permeable membranes, in one case the urea from the blood passing through the membrane into a washing liquid, while in the other case blood flow. liquid with the urea dissolved therein passes through the membrane, leaving the proteins and blood cells behind.
  • OMPI, - W1P0, ⁇ *> 1 can be kept and no dangerous reaction products arise for the organism.
  • the process according to the invention for removing urea from blood washing liquids or blood liquids 5 by treating these liquids with an organic solid having at least one aldehyde group per molecule and subsequently separating this solid from the liquids is characterized in that little is used as the organic solid with aldehyde groups - 10 least used a compound in which aldehyde groups are activated and masked by a proton-containing substituent of the second order.
  • Second-order substituents are those which exert an electron-withdrawing effect on the adjacent groups 15, the effect increasing from the group -C00NH 2 via ⁇ * the group -COOH and the group -CHO to the group -S0 3 H.
  • Second-order substituents reference is made to Klages "Textbook of Organic Chemistry", 1957, Volume II, page 323 ff. 20.
  • the groups -COOH, -CONH 2 , -S0_H and -S0 2 NH 2 come into consideration according to the invention, for example.
  • the groups -COOH, -CHO and -SO ⁇ H are preferred as 25 second-order substituents. Among them, the carboxyl group and the aldehyde group are particularly preferred.
  • Second order substituents consist of 30 different groups that fall under this term, and some of the substituents can also consist of first order substituents. So it is enough for example in the preferred embodiment of the carboxyl groups that the second-order substituents at least partially consist of such carboxyl groups.
  • the aldehyde used in this invention enthal ⁇ Tenden compounds may cycloaliphatic shear, aromatic ⁇ äer heteroaromatic nature aliphatic, "be” patii.olefinische, aromatic and heteroaromatic compounds are preferred ,, since they have the Mesomerie the double bonds of the electron withdrawing effect of the secondary substituent favor on the aldehyde group. It is therefore expedient to use organic compounds in which the second-order substituent is separated from an aldehyde group by a carbon-carbon bond or an even number of carbon atoms which are bonded by one or more conjugated double bonds.
  • Second order substituent is separated from an adjacent aldehyde group only by two carbon atoms which are connected by an olefinic double bond or are part of an aromatic or heteroaromatic ring.
  • Examples of such compounds are glyoxylic acid, maleicaldehyde acid and its derivatives, such as mucohalic acid, phenylogens of maleic aldehyde acid and the derivatives thereof, such as phthalaldehyde acid, o-phthalaldehyde acid and pyromellitic dialdehyde acid and its derivatives, and heterophenylogens of maleic aldehyde acid, such as nicotine and their derivatives. Phthalaldehyde acid and pyromellitic dialdehyde acid and their derivatives are preferred,
  • OMPI ⁇ 1 especially phthalaldehyde acid.
  • the compounds may also be polymeric in nature 'and several Aldehydgrup- pqn in the molecule.
  • the hydroxylactone has the following formula II.
  • the masking of the aldehyde group by addition of the second-order proton-containing substituent need not be carried out intramolecularly, but can also take place intermolecularly if intramolecular 25th hydroxylactone formation would only be possible with the formation of ring systems, which for steric reasons are unstable.
  • the activity of the compounds used according to the invention having at least one aldehyde group in the molecule is further increased by the simultaneous use of an acidic, preferably a strongly acidic, cation exchange agent.
  • an acidic, preferably a strongly acidic, cation exchange agent preferably a strongly acidic cation exchange agent.
  • a strongly acidic cation exchanger based on divinylbenzene-crosslinked polystyrene sulfonic acid can be used.
  • the acidic cation exchanger ⁇ is expediently used in an amount of 0.01 to 10 g, preferably in an amount of 0.1 to 1 g, per gram of the organic compounds with aldehyde groups.
  • Ver ⁇ above-described compounds in carrier-fixed form to be used, so that they can be held in a column, "through which the washing liquid blood or blood liquid for Eliminie ⁇ tion of urea may be performed.
  • 2 ⁇ proton-containing substituents of the second order are activated and masked, urea, specifically selective towards amino acids, such as glycine, from aqueous media, such as dialysis fluid and diafiltrate, rapidly and completely eliminated under approximately physiological conditions
  • the method according to the invention is particularly suitable for the dialysis or diafiltration of human or animal blood or hemofiltrate.
  • a solution of 10 g of o-phthalaldehyde acid in 2 1 dialysis solution at 40 was obtained from a storage vessel by means of an acid with adsorption carbon which had been prewashed, dried and sterilized ° C and at a rate of 100 ml / min. pumped through the circuit until no more o-phthalaldehyde acid could be detected in the stock solution.
  • A 2-carboxybenzaldehyde (o-phthalaldehyde acid)
  • B 2-carboxyacetophenone
  • C 2-carboxybenzophenone 10
  • D o-phthalaldehyde
  • E mucochloric acid
  • F mucobromic acid
  • G c (-angelicalactone H: xanthydrol
  • OM with 2-carboxybenzaldehyde (A) increased considerably by adding the activated carbon (up to 6.3 ⁇ .
  • the mixture was stirred at 40 ° C. take a sample after 1, 2, 3 and 4 hours, filter and adjust to pH 7.2 with phosphate buffer solution. The urea content of the sample was then determined according to Berthelot. Try starting after. after after after
  • Example 3 The experiment was carried out as in Example 3, but in each case 100 ml of a 0.9% NaCl solution were used, which contained 5 mmol of the amino acid glyamine instead of 5 mmol (corresponding to 0.3 g) of urea. Samples were taken after 4 hours from the mixtures stirred at 40 ° C. and the glycine content was determined photometrically by means of a ninhydrin reaction.
  • the concentration of the starting solution with glycine was 392 mg, that of the starting solution with urea at 300 mg%.
  • Fresh bovine blood was adjusted to a hematocrit of 25% with physiological saline solution. With a blood flow of 200 ml / min. and a transmembrane pressure difference of 300 mm Hg were 50 ml / min over a polyamide membrane. Filtered protein-free hemofiltrate. In each case 100 ml thereof were mixed with 300 mg urea and stirred with the following adsorbents at 38 ° C. for 4 hours:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procede d'extraction de l'uree contenue dans les effluents de lavage du sang ou dans les liquides sanguins, selon lequel ces liquides sont traites a l'aide d'une substance organique solide qui est ensuite separee des liquides, ce procede utilisant comme substance organique au moins un compose possedant au minimum un groupe aldehyde par molecule, compose dans lequel les groupes aldehydes sont actives ou masques a l'echelle intra ou intermoleculaire par un substituant portant un proton, a savoir, selon le cas, -COOH, -CH0 ou -SO3H. Le procede est applicable a la dialyse ou a l'ultrafiltration a l'aide de membranes semipermeables et permet une elimination rapide et importante de l'uree en utilisant une quantite relativement faible de substance organique, sans engendrer de substances dangereuses pour l'organisme.
PCT/DE1978/000016 1977-08-30 1978-08-05 Procede d'extraction de l'uree des effluents de lavage du sang ou des liquides sanguins Ceased WO1979000115A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR7808683A BR7808683A (pt) 1977-08-30 1978-08-05 Aperfeicoamento relativo a remocao de ureia de solucoes aquosas contendo a mesma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE7709703A SE407515B (sv) 1977-08-30 1977-08-30 Forfarande for avlegsnande av urinemne ur blodtvettvetskor eller blodvetskor
SE7709703 1977-08-30

Publications (1)

Publication Number Publication Date
WO1979000115A1 true WO1979000115A1 (fr) 1979-03-08

Family

ID=20332114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1978/000016 Ceased WO1979000115A1 (fr) 1977-08-30 1978-08-05 Procede d'extraction de l'uree des effluents de lavage du sang ou des liquides sanguins

Country Status (6)

Country Link
JP (1) JPS5493900A (fr)
DE (1) DE2856941D2 (fr)
FR (1) FR2401664A1 (fr)
GB (1) GB2020996B (fr)
SE (1) SE407515B (fr)
WO (1) WO1979000115A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037520A3 (en) * 1980-03-26 1982-06-16 Sartorius Gmbh. Use of phenol-aldehyde resins for the removal of substances from liquids, especially of urinous substances
WO2004078797A1 (fr) * 2003-02-28 2004-09-16 Baxter International Inc. Cetaloaldehydes macromoleculaires

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8301035A (nl) * 1983-03-23 1984-10-16 Organon Teknika Bv Macromoleculair materiaal met carbonylgroepen geschikt als sorbent voor stikstofverbindingen.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL288010A (fr) *
DE2305186A1 (de) * 1972-02-04 1973-08-09 Rhone Poulenc Sa Alkenylaromatische polymere mit funktionellen alpha-ketoaldehydgruppen
FR2235722A1 (fr) * 1973-07-05 1975-01-31 Univ Strathclyde
FR2322155A1 (fr) * 1975-08-28 1977-03-25 Rhone Poulenc Ind Supports mineraux greffes par des derives silicies
FR2350864A1 (fr) * 1974-05-06 1977-12-09 Bellco Spa Procede pour la regeneration d'un liquide dialysant dans les processus d'hemodialyse

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL288010A (fr) *
DE2305186A1 (de) * 1972-02-04 1973-08-09 Rhone Poulenc Sa Alkenylaromatische polymere mit funktionellen alpha-ketoaldehydgruppen
FR2235722A1 (fr) * 1973-07-05 1975-01-31 Univ Strathclyde
FR2350864A1 (fr) * 1974-05-06 1977-12-09 Bellco Spa Procede pour la regeneration d'un liquide dialysant dans les processus d'hemodialyse
FR2322155A1 (fr) * 1975-08-28 1977-03-25 Rhone Poulenc Ind Supports mineraux greffes par des derives silicies

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037520A3 (en) * 1980-03-26 1982-06-16 Sartorius Gmbh. Use of phenol-aldehyde resins for the removal of substances from liquids, especially of urinous substances
WO2004078797A1 (fr) * 2003-02-28 2004-09-16 Baxter International Inc. Cetaloaldehydes macromoleculaires
US6861473B2 (en) 2003-02-28 2005-03-01 Baxter International Inc. Macromolecular ketoaldehydes

Also Published As

Publication number Publication date
DE2856941D2 (en) 1980-11-13
SE7709703L (sv) 1979-03-01
GB2020996B (en) 1982-07-21
FR2401664A1 (fr) 1979-03-30
SE407515B (sv) 1979-04-02
JPS5493900A (en) 1979-07-25
GB2020996A (en) 1979-11-28

Similar Documents

Publication Publication Date Title
EP0302948B1 (fr) Procédé d'obtention de stéviosides à partir de plantes
DE2646854C2 (fr)
DE2219639C3 (de) Verfahren zur Abtrennung einer im wesentlichen aus hochmolekularen Verbindungen bestehenden Fraktion bei der Reinigung von Zuckersaft
EP0894083A1 (fr) Creatine pyruvates et leur procede de preparation
EP0186836A2 (fr) Procédé de concentration de solutions aqueuses de composés organiques, contenant des sels, par diminution simultanée de la teneur en sel
EP0281678B1 (fr) Procédé pour la préparation de sels alcalins d'acide humique de faible poids moléculaire
WO1979000115A1 (fr) Procede d'extraction de l'uree des effluents de lavage du sang ou des liquides sanguins
EP0537429B1 (fr) Huminates modifiés, procédé pour leur préparation et applications
DE69414020T2 (de) Verfahren zur Gewinnung von Cyclodextrin
DE69810345T2 (de) Verfahren und anlage zur extraktion und konzentration von tanninen aus holz und anderen natürlichen produkten
DE3922278C2 (de) Verfahren zur herstellung von freiem (epsilon)-polylysin
DE69525948T2 (de) Verfahren zur wiedergewinnung von zitronensäure
DE1518314C3 (de) Verfahren zur Isolierung von Bacitracin
DE2537123A1 (de) Verfahren zur herstellung von albumin
DE916904C (de) Verfahren zur Gewinnung von Streptomycin aus waessrigen Loesungen
DE2619163A1 (de) Verfahren zur regenerierung der dialysierfluessigkeit im haemodialyseverfahren
DE1065257B (de) Verfahren zur H erstellung eines Eiweißpräparates aus Blutplasma
NZ335344A (en) Producing tartaric acid from potassium hydrogentartrate (KHT)
DE2424118A1 (de) Verfahren zur herstellung von hochreinem kallikrein
DE3877641T2 (de) Isolierung von neutralen aminosaeuren bei hohen ph-werten.
DE908697C (de) Verfahren zur Verarbeitung von Seren, insbesondere Molke
AT376884B (de) Verfahren zur inaktivierung von vermehrungsfaehigen krankeitserregern
DE964863C (de) Verfahren zur Herstellung hydrierter Formylpteroinsaeuren
DE2024062C3 (de) Verfahren zur Abtrennung und Ge winnung von L Lysin
DE1008448B (de) Verfahren zur Gewinnung und Reinigung von Polymyxin

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): BR CH DE GB SU US

Kind code of ref document: A1

Designated state(s): BR CH DE GB SU US

REF Corresponds to

Ref document number: 2856941

Country of ref document: DE

Date of ref document: 19801113

Format of ref document f/p: P